BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29176861)

  • 1. Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.
    Gaiser MR; Skorokhod A; Gransheier D; Weide B; Koch W; Schif B; Enk A; Garbe C; Bauer J
    PLoS One; 2017; 12(11):e0188602. PubMed ID: 29176861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF mutation testing in melanoma: results from a German observational multicenter study.
    Hartmann A; Schirmacher P; Sterlacci W; Koch W; Liesenfeld DB; Schif B; Garbe C
    Virchows Arch; 2019 Jan; 474(1):71-78. PubMed ID: 30406424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
    Siroy AE; Boland GM; Milton DR; Roszik J; Frankian S; Malke J; Haydu L; Prieto VG; Tetzlaff M; Ivan D; Wang WL; Torres-Cabala C; Curry J; Roy-Chowdhuri S; Broaddus R; Rashid A; Stewart J; Gershenwald JE; Amaria RN; Patel SP; Papadopoulos NE; Bedikian A; Hwu WJ; Hwu P; Diab A; Woodman SE; Aldape KD; Luthra R; Patel KP; Shaw KR; Mills GB; Mendelsohn J; Meric-Bernstam F; Kim KB; Routbort MJ; Lazar AJ; Davies MA
    J Invest Dermatol; 2015 Feb; 135(2):508-515. PubMed ID: 25148578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma.
    Saadani H; van der Hiel B; Aalbersberg EA; Zavrakidis I; Haanen JBAG; Hoekstra OS; Boellaard R; Stokkel MPM
    J Nucl Med; 2019 Nov; 60(11):1545-1552. PubMed ID: 31481581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response.
    Pinto R; De Summa S; Strippoli S; Pilato B; Azzariti A; Guida G; Guida M; Tommasi S
    Oncotarget; 2016 May; 7(18):25135-49. PubMed ID: 26863566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.
    Bucheit AD; Chen G; Siroy A; Tetzlaff M; Broaddus R; Milton D; Fox P; Bassett R; Hwu P; Gershenwald JE; Lazar AJ; Davies MA
    Clin Cancer Res; 2014 Nov; 20(21):5527-36. PubMed ID: 25165098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
    Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
    Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies.
    Lamy PJ; Castan F; Lozano N; Montélion C; Audran P; Bibeau F; Roques S; Montels F; Laberenne AC
    J Mol Diagn; 2015 Jul; 17(4):366-73. PubMed ID: 25952101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Sun Exposure and Tanning Patterns on Next-Generation Sequencing Mutations in Melanoma.
    Loo K; Soliman I; Renzetti M; Li T; Wu H; Reddy S; Olszanski AJ; Farma JM
    J Surg Res; 2020 Oct; 254():147-153. PubMed ID: 32445930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy.
    Akman T; Oztop I; Baskin Y; Akbarpour M; Unal OU; Oflazoglu U; Ellidokuz H; Lebe B
    Med Oncol; 2015 Jan; 32(1):440. PubMed ID: 25502087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.
    Gonzalez-Cao M; Mayo de Las Casas C; Jordana Ariza N; Manzano JL; Molina-Vila MÁ; Soriano V; Puertolas T; Balada A; Soria A; Majem M; Montagut C; Muñoz E; Rodriguez-Abreu D; Perez E; Garcia A; Cortes J; Drozdowskyj A; Karachaliou N; Rosell R;
    Melanoma Res; 2018 Jun; 28(3):195-203. PubMed ID: 29481492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.
    Wheler J; Yelensky R; Falchook G; Kim KB; Hwu P; Tsimberidou AM; Stephens PJ; Hong D; Cronin MT; Kurzrock R
    BMC Cancer; 2015 Feb; 15():61. PubMed ID: 25886620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which melanoma patient carries a BRAF-mutation? A comparison of predictive models.
    Eigentler T; Assi Z; Hassel JC; Heinzerling L; Starz H; Berneburg M; Bauer J; Garbe C
    Oncotarget; 2016 Jun; 7(24):36130-36137. PubMed ID: 27150060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
    Halait H; Demartin K; Shah S; Soviero S; Langland R; Cheng S; Hillman G; Wu L; Lawrence HJ
    Diagn Mol Pathol; 2012 Mar; 21(1):1-8. PubMed ID: 22306669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis--A Single-Center Study.
    Rouzbahman M; Kamel-Reid S; Al Habeeb A; Butler M; Dodge J; Laframboise S; Murphy J; Rasty G; Ghazarian D
    J Low Genit Tract Dis; 2015 Oct; 19(4):350-3. PubMed ID: 26225944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.
    van den Hurk K; Balint B; Toomey S; O'Leary PC; Unwin L; Sheahan K; McDermott EW; Murphy I; van den Oord JJ; Rafferty M; FitzGerald DM; Moran J; Cummins R; MacEneaney O; Kay EW; O'Brien CP; Finn SP; Heffron CC; Murphy M; Yela R; Power DG; Regan PJ; McDermott CM; O'Keeffe A; Orosz Z; Donnellan PP; Crown JP; Hennessy BT; Gallagher WM
    Melanoma Res; 2015 Jun; 25(3):189-99. PubMed ID: 25746038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
    Tetzlaff MT; Pattanaprichakul P; Wargo J; Fox PS; Patel KP; Estrella JS; Broaddus RR; Williams MD; Davies MA; Routbort MJ; Lazar AJ; Woodman SE; Hwu WJ; Gershenwald JE; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2015 Aug; 46(8):1101-10. PubMed ID: 26058727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.